This clinical trial studies the effect of sublimated mare milk supplement on patients with hepatitis C.
Chronic viral hepatitis C is one of the medical, social and economic public health problems throughout the world. In majority of patients with chronic viral hepatitis C, dysbiotic changes are detected in the intestinal tract. Disturbances of microbial equilibrium are associated with the degree of inflammation, morphological changes in the liver, nature of the course and the stage of the disease. These dysbiotic changes and and associated immune disorders can significantly aggravate the course of immune processes in the liver, converting hepatitis C infection to a chronic disease. Mare milk is frequently reported for having therapeutic and dietary properties, which are initially associated with a specific chemical composition and certain physical properties of the product. It contains a total of about 40 biologically active components, the most important of them vitamins A, C, B1, B2, B6, B12, amino acids, enzymes and trace elements, there are low molecular weight peptides, lactalbumins and globulins. The use of mare milk can contribute to the restoration of impaired functions of damaged organs and tissues, and play the role of an auxiliary pathogenetic therapy, primarily in certain chronic diseases of the digestive system, including chronic viral hepatitis C. Mare milk can also be used as a powder supplement through sublimation process. In this trial, the effect of this supplement consisting of sublimated mare milk on hepatitis C patients will be evaluated. There will be two parallel groups: Interventional (sublimated mare milk supplement with standard treatment) and Standard treatment group. Differences in laboratory characteristics will be quantitively analyzed between groups.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
100
Supplement consisting of sublimated mare's milk with single-dose 20 mg sachet. The supplement is dissolved in 36-27 degrees of Celsius water and taken 15-20 minutes before meal.
For hepatitis virus C genotype 1: sofosbuvir 400 mg + lepidavir 90 mg for 12 weeks OR sofosbuvir 400 mg + daclatasvir 60 mg for 12 weeks; For hepatitis virus C genotypes 2 and 3: sofosbuvir 400 mg + daclatasvir 60 mg for 12 weeks.
Asfendiyarov Kazakh National Medical University
Almaty, Kazakhstan
Change in liver function.
Change in liver function will be assessed from biochemical blood results of alanine transaminase and aspartate transaminase.
Time frame: Baseline, 2 weeks, 4 weeks, 8 weeks
Change in urine test.
Proportion of patients with deviations from normal range of urine test.
Time frame: Baseline, 2 weeks, 4 weeks, 8 weeks
Changes in gut microbiota composition.
Proportions of aerobic and anaerobic bacteria will be assessed from stool samples using MiSeq Sequencing System.
Time frame: Baseline, 2 weeks, 4 weeks, 8 weeks
Intestinal immune status changes.
Level of immune status markers (Immunoglobulin G, Immunoglobulin M) will be detected from blood samples.
Time frame: Baseline, 2 weeks, 4 weeks, 8 weeks
Changes in phospholipids spectrum of lymphocyte membranes.
Detection of changes in phospholipids spectrum of lymphocyte membranes (phosphatidylethanolamine, phosphatidylserine, phosphatidylcholine, sphingomyelin, lysophosphatidylcholine) will be performed using the thin-layer chromatography method.
Time frame: Baseline, 2 weeks, 4 weeks, 8 weeks
Changes in degree of liver fibrosis.
Liver fibrosis will be evaluated using transient elastography method.
Time frame: Baseline, 2 weeks, 4 weeks, 8 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.